Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell MalignanciesBrynn B. Duncan, Nirali N. Shah, Hao‐Wei Wang et al.|Blood|2024Cited by 4
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategiesAlexandra Dreyzin, Nirali N. Shah, Anne Marijn Kramer et al.|Cytotherapy|2025Cited by 1
CD22 CAR T-Cells Manufactured in Prodigy System and in Bag Culture Yield Equivalent Responses for B-ALLAlexandra Dreyzin, Nirali N. Shah, Anne Marijn Kramer et al.|Transplantation and Cellular Therapy|2024Cited by 0